EPT Disclosure

13 Jun 2006 12:18

GoldmanSachs International13 June 2006 FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION Name of exempt principal trader Goldman Sachs International Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Class of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 1) Date of dealing 12 June 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 0 Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 13158 13.065 GBP 13.065 GBP (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)e.g. CFD (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money purchasing, which the option relates price American, date paid/received pere.g. call varying etc. (Note 5) European unit (Note 3)option etc. (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. Date of disclosure 13 June 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which connected Astrazeneca Nature of connection (Note 6) Advisor Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange